Market Closed -
Nasdaq
01:30:00 02/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.22
USD
|
+2.52%
|
|
+2.52%
|
-10.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
636.2
|
577.8
|
168.1
|
31.21
|
60.62
|
54.73
|
-
|
-
|
Enterprise Value (EV)
1 |
449.2
|
318.1
|
-6.56
|
-45.36
|
60.62
|
54.73
|
54.73
|
54.73
|
P/E ratio
|
-7.57
x
|
-4.21
x
|
-1.38
x
|
-0.29
x
|
5.04
x
|
-1.87
x
|
-2.77
x
|
-61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-8.49
x
|
-4.85
x
|
-1.43
x
|
-0.3
x
|
-0.85
x
|
-0.71
x
|
-0.54
x
|
-
|
EV / FCF
|
-91,86,608
x
|
-57,79,416
x
|
-16,31,542
x
|
-3,20,148
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.43
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
31,605
|
41,451
|
43,652
|
43,774
|
44,574
|
44,861
|
-
|
-
|
Reference price
2 |
20.13
|
13.94
|
3.850
|
0.7129
|
1.360
|
1.220
|
1.220
|
1.220
|
Announcement Date
|
16/03/20
|
18/03/21
|
17/03/22
|
23/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-74.96
|
-119
|
-117.4
|
-104
|
-71.05
|
-77.6
|
-100.6
|
-
|
EBIT
1 |
-75.81
|
-120.2
|
-118.8
|
-105.4
|
-71.67
|
-77
|
-47.7
|
-1.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-72.96
|
-119.7
|
-119.1
|
-105.9
|
12.53
|
-77
|
-46.7
|
-0.9
|
Net income
1 |
-72.96
|
-119.7
|
-119.1
|
-105.9
|
12.16
|
-77
|
-46.7
|
-0.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.660
|
-3.310
|
-2.780
|
-2.420
|
0.2700
|
-0.6533
|
-0.4400
|
-0.0200
|
Free Cash Flow
|
-69.25
|
-99.98
|
-103
|
-97.48
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
18/03/21
|
17/03/22
|
23/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-32.62
|
-27.96
|
-29.42
|
-27.77
|
-22.98
|
-25.26
|
-25.22
|
-15.73
|
-21.09
|
-9.627
|
-16
|
-16
|
-20
|
-25
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-32.61
|
-28.23
|
-29.83
|
-28.05
|
-22.97
|
-25.03
|
-24.96
|
67.48
|
-21.58
|
-8.408
|
-16
|
-16
|
-20
|
-25
|
-
|
Net income
1 |
-32.61
|
-28.23
|
-29.83
|
-28.05
|
-22.97
|
-25.03
|
-24.96
|
67.48
|
-21.58
|
-8.785
|
-16
|
-16
|
-20
|
-25
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7500
|
-0.6500
|
-0.6800
|
-0.6400
|
-0.5200
|
-0.5700
|
-0.5700
|
1.520
|
-0.4800
|
-0.2000
|
-0.3600
|
-0.0800
|
-0.1000
|
-0.1300
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
17/03/22
|
10/05/22
|
09/08/22
|
08/11/22
|
23/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
14/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
187
|
260
|
175
|
76.6
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-69.3
|
-100
|
-103
|
-97.5
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-47.4%
|
-54.4%
|
-56.2%
|
-86.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-43.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
167
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.870
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.59
|
1.18
|
2.46
|
0.27
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
18/03/21
|
17/03/22
|
23/03/23
|
14/03/24
|
-
|
-
|
-
|
Last Close Price
1.22
USD Average target price
2
USD Spread / Average Target +63.93% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.29% | 54.73M | | -1.17% | 104B | | +2.87% | 97.47B | | +5.01% | 22.25B | | -14.77% | 21.68B | | -8.63% | 18.2B | | -39.98% | 17.02B | | -13.21% | 16.36B | | +8.55% | 14.39B | | +35.75% | 12.37B |
Bio Therapeutic Drugs
|